Vasogen Inc., of Toronto, appointed Ronald Cresswell and Calvin Stiller to its board...XOMA Ltd., of Berkeley, Calif., appointed Robert Gundel vice president, scientific corporate development...Mary Haak-Frendscho vice president, preclinical research and development

and Robert Quinn for CIT business and science applications...Idenix Pharmaceuticals Inc., of Cambridge, Mass., appointed Susan Koppy senior vice president, business and corporate development

Affymax Inc., of Palo Alto, Calif., appointed Paul Cleveland chief financial officer and executive vice president of corporate development, and Christopher Damman vice president of business development

Encysive Pharmaceuticals, of Houston, appointed Paul Manierre vice president and general counsel...Epitome Biosystems, of Waltham, Mass., appointed Thomas Joos and Forest White to its scientific advisory board...Genizon BioSciences, of Montreal, appointed Claude Lambert vice president and chief financial officer, and Renno Schuurmans vice president of business development, Europe

Richard Murray senior vice president, chief scientific and technical officer...and Eric Emery vice president, manufacturing, and as the Minnesota site head

and Joseph Sarret corporate counsel and director, business development...and Gary Arlen Smith vice president and general counsel

Oragenics Inc., of Alachua, Fla., appointed Robert Zahradnik acting president and CEO...Sirna Therapeutics Inc., of San Francisco, appointed Michael French senior vice president for corporate development

Alfacell Corp., of Bloomfield, N.J., appointed Jacob Maizel and Susanna Rybak to its scientific advisory board...Ceragenix Pharmaceuticals, of Denver, appointed Russell Allen vice president of corporate development...CuraGen Corp., of New Haven, Conn., appointed Michael Astrue and Frank Armstrong to its board

Merrimack Pharmaceuticals, of Cambridge, Mass., appointed Dan Littman and James Marks to its scientific advisory board...Metabolex Inc., of Hayward, Calif., appointed Patrick James Doyle chief corporate development officer...Prometic Life Sciences Inc., of Montreal, appointed Stephane Archambault vice president of finance, Vincent Taillefer vice president of corporate development, and Janis Peleshok director of business development

Gabe Leung executive vice president and president of oncology...Anker Lundemose executive vice president and president of Prosidion...and Karsten Witt senior medical officer for drug safety

Generex Biotechnology Corp., of Toronto, appointed Mindy Allport-Settle and Peter Amanatides to its regulatory compliance committee...Imagenetix Inc., of San Diego, formed a scientific and medical advisory board to include Jonathan Adachi, Dan Gallaher and Robert Beeten

The biolitec Group, of Jena, Germany, appointed Carl Siekmann vice president, corporate development...Topigen Pharmaceuticals Inc., of Montreal, appointed Gary Lessing and Michael Atkin to its board

MaxCyte Inc., of Gaithersburg, Md., appointed Madhusudan Peshwa vice president, research and development...Memory Pharmaceuticals Corp., of Montvale, N.J., appointed Tony Scullion president, and David Lowe to its board...Millennium Pharmaceuticals Inc., of Cambridge, Mass., promoted Anna Protopapas to senior vice president, corporate development, and David Schenkein senior vice president, clinical research

Gentris Corp., of Morrisville, N.C., appointed Deborah Oronzio vice president of business development and marketing, and Sandra Sonnessa vice president of corporate development...Kalypsys Inc., of San Diego, appointed John McKearn CEO, and Philip Needleman and August Watanabe to its board

Biocom, of San Diego, appointed Jack Lief chairman and added new board members Dana Di Ferdinando, Larry Fitch, Mary Lyons, Randall Woods and Kleanthis Xanthopoulos...Theratechnologies Inc., of Montreal, appointed James Sutton vice president, clinical development and regulatory affairs, and Robert Goyer to its board

Paratek Pharmaceuticals Inc., of Boston, appointed John Dunphy vice president and chief financial officer...PharMetrics Inc., of Watertown, Mass., appointed Stephen Boccuzzi vice president and chief scientific officer...Solexa Inc., of Cambridge, UK, appointed Peter Lundberg vice president and chief technical officer

and Wayne Vaz, director, business development and strategic planning...Vertex Pharmaceuticals Inc., of Cambridge, Mass., appointed Victor Hartmann executive vice president, strategic and corporate development

Altus Pharmaceuticals Inc., of Cambridge, Mass., appointed Martin Williams vice president and head of corporate development...HTG Inc., of Tucson, Ariz., appointed Daniel Von Hoff and Raymond Woosley to its scientific advisory board

Sirtris Pharmaceuticals Inc., of Boston, appointed Michael Milburn senior vice president of research and corporate development...Vasogen Inc., of Toronto, appointed Jay Kleiman chief medical officer and head of cardiovascular development, Michael Shannon vice president of medical affairs, and Marguerite Ethier general counsel and corporate secretary